GE HealthCare has dosed the first patient in a Phase 2/3 trial of a manganese-based MRI contrast agent and secured FDA clearance for three next-generation SIGNA MRI systems. The contrast agent aims to ...
CHICAGO--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) today announced the 510(k) submissions to the U.S. Food and Drug Administration (FDA) seeking clearance for next-generation SIGNA™ MRI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results